( EuronextParis:SAN, NYSE:SNY )

News from Sanofi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 14, 2017, 07:00 ET Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice

A new randomized clinical trial, TAKE CONTROL1, demonstrated better control of blood sugar (HbA1c) without increasing the risk of hypoglycemia in...


Sep 13, 2017, 07:00 ET Daily Blood Glucose Measures in Phase 3 Clinical Trials Demonstrated Better Stability with Sanofi's Toujeo® vs. Insulin Glargine 100 Units/mL

In a new analysis1 of late stage clinical trials,2-4 adults with type 2 diabetes treated with Sanofi's Toujeo® (insulin glargine 300 Units/mL,...


Sep 12, 2017, 07:01 ET Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL

In certain adults with type 2 diabetes, Sanofi's Soliqua® 100/33 (insulin glargine & lixisenatide injection, 100 Units/mL & 33 mcg/mL)...


Sep 01, 2017, 14:00 ET Sanofi Receives Tentative FDA Approval of Admelog® (insulin lispro injection) 100 Units/mL

Sanofi announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100...


Jul 31, 2017, 07:30 ET Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER

Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2017 Change Change at CER...


Jun 11, 2017, 11:01 ET Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

Sanofi and Regeneron Pharmaceuticals, Inc. today announced positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with...


Jun 10, 2017, 13:01 ET In Senior Adults Treated with Basal Insulin, Switching to Sanofi's Toujeo® Halved Hypoglycemia Risk

Sanofi announced today new evidence from a real-world observational study demonstrating significantly less risk of documented hypoglycemia with...


Jun 10, 2017, 13:01 ET New Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c by More Than 2 Percent in Patients with Screening Levels Greater than 9 Percent

Sanofi announced today that Soliqua® 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL lowered mean blood sugar...


Jun 04, 2017, 10:00 ET Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

Sanofi and Regeneron Pharmaceuticals, Inc. today announced positive preliminary results with investigational REGN2810, a checkpoint inhibitor...


May 22, 2017, 17:47 ET Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients

Sanofi and Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the...


May 11, 2017, 08:30 ET Allegra® Allergy Gears Up for Bike to Work Day Across the U.S.

Sanofi Consumer Healthcare – the makers of Allegra® Allergy – announced today that it is supporting Bike to Work Day events across the country as a...


May 02, 2017, 08:30 ET Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment

Honestly RA, a new survey of more than 1,000 people in the United States living with rheumatoid arthritis (RA), found that even after treatment,...


Apr 28, 2017, 07:30 ET Sanofi Delivers Robust Q1 2017 Financial Results

Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2017 Change Change at CER Change...


Apr 25, 2017, 08:00 ET Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new...


Apr 03, 2017, 09:00 ET Sanofi lanza la primera ACT® Kids Toothpaste en Estados Unidos

Sanofi anunció hoy el lanzamiento de ACT® Kids Toothpaste, una nueva pasta dental anticaries con fluoruro que ha sido creada especialmente para los...


Apr 03, 2017, 09:00 ET Sanofi Launches First-Ever ACT® Kids Toothpaste in the U.S.

Sanofi announced today the launch of ACT® Kids Toothpaste, a new anti-cavity fluoride toothpaste that is specially developed for kids two years of...


Apr 02, 2017, 13:01 ET Switching to Sanofi's Toujeo® Showed Significant Reductions in Blood Sugar and Significantly Lower Incidence of Hypoglycemia in a Real-World Observational Study

Sanofi announced today the presentation of a new observational study1 in real-world clinical practice demonstrating significantly lower risk of...


Mar 28, 2017, 11:40 ET Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab)...


Mar 22, 2017, 07:30 ET Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the extension of the Multiple Myeloma Journey Partners Program...


Mar 21, 2017, 07:30 ET Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S.

Sanofi Consumer Healthcare – the makers of new Xyzal® Allergy 24HR, which is now available on retail shelves nationwide – revealed today the...


Feb 27, 2017, 08:30 ET Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that detailed results from the Phase 3 CHRONOS study will be presented as a...


Feb 08, 2017, 07:30 ET Sanofi Delivers 2016 Sales and Business EPS Growth at CER

Sanofi (NYSE: SNY; EURONEXT: SAN) Q4 2016 Change Change (CER) 2016...


Feb 08, 2017, 03:05 ET Sanofi - Interview du Directeur Général - Résultats 2016 (vidéo)

Sanofi, un leader mondial et diversifié de la santé, publie ses résultats pour l'année 2016. Le Directeur Général du Groupe, Olivier Brandicourt,...


Feb 08, 2017, 03:02 ET Sanofi CEO Interview - FY 2016 Results (video)

Sanofi, a global and diversified healthcare leader, reports results for 2016. Olivier Brandicourt, Chief Executive Officer of Sanofi, comments on...


Feb 01, 2017, 08:00 ET Sanofi's Xyzal® Allergy 24HR Approved for Over-the-Counter Use in the United States

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Xyzal® Allergy 24HR as an over-the-counter (OTC) treatment for the...